Leap Therapeutics

At Leap Therapeutics, we believe that teamwork is the foundation of our success. Whether we’re deep in research, collaborating on strategies, or enjoying a fun scavenger hunt to recharge, our Leapsters show relentless dedication and support for one another. It's through hard work, shared goals, and the friendships we’ve built that we continue to make a meaningful impact on cancer patients’ lives. Together, we’re not just colleagues – we’re a team driving change.

The #Leapsters had a great time during our summer outing at Spin sharpening our ping pong skills!??

We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world. https://lnkd.in/dj5gBmkF

March is Colorectal Cancer Awareness Month. Through our DeFianCe Phase 2 CRC clinical trial, we're reminded of the unmet medical need of these patients and the dedication from our clinical sites and physicians aiming for better outcomes. https://lnkd.in/e3S8CwVj

Reminder to join Drs. Pelster & Wainberg today at 8:30 AM ET, for their firsthand accounts on DeFianCe, our 2L CRC trial of DKN-01 in combination with Bevacizumab and chemo. Link here: https://lnkd.in/ejiqtJ-9

Join us at ASCO GI 2024 for updates on Part A of our DeFianCe #colorectalcancer study at Moscone West on Jan 20th from 6:30-9:30AM PST at poster G8. Also, tune in on Jan 23, 8:30 am ET to hear insights from the treating physicians. Details and links:

Join us at J.P. Morgan’s 42nd Annual Healthcare Conference, 1/10/24, 1:30pm PT, to hear from our CEO Doug Onsi on Leap and our lead program, DKN-01. #JPM2024 https://lnkd.in/eemgN4wZ

BioSpace spotlights DKN-01 as one of “10 Promising Therapies for Hard-to-Treat Cancers.” With randomized controlled trials underway in GC and CRC, we are heading into an exciting phase of development and committed to bringing new therapies to patients. https://lnkd.in/dsFvNc9t